PURPOSE: To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage nivolumab/ipilimumab in patients with tumors unresponsive to nivolumab monotherapy. METHODS: Eligible patients with treatment-naive ccRCC received nivolumab until progressive disease (PD), toxicity, or completing 96 treatment weeks (part A). Patients with PD before or stable disease at 48 weeks could receive salvage nivolumab/ipilimumab (part B). The primary end point was improvement in 1-year progression-free survival in patients with tumor PD-L1 expression > 20% versus 0%. RESULTS: One hundred twenty-three patients were enrolled. The objective response rate (ORR) was 34.1% (95% CI, 25.8 to 43.2). ORR by International Metastatic RCC Database Consortium category was favorable-risk 57.1%, intermediate-risk/poor-risk 25.0%, and by sarcomatoid features 36.4%. The ORR was 26.9%, 50.0%, and 75.0% for patients with the tumor PD-L1 expression of 0, 1-20, or > 20%, respectively (trend test P value = .002). The median duration of response was 27.6 (19.3 to not reached) months, with 26 of 42 responders including 17 of 20 with favorable-risk disease remaining progression-free. The 1-year progression-free survival was 34.6% and 75.0% in the PD-L1 = 0% and > 20% categories, respectively (P = .050). Ninety-seven patients with PD or prolonged stable disease were potentially eligible for part B, and 35 were enrolled. The ORR for part B was 11.4%. Grade ≥ 3 treatment-related adverse events occurred in 35% of patients on nivolumab and 43% of those on salvage nivolumab/ipilimumab. CONCLUSION: Nivolumab monotherapy is active in treatment-naive ccRCC. Although efficacy appears to be less than that of nivolumab/ipilimumab in patients with intermediate-risk/poor-risk disease, favorable-risk patients had notable benefit. Efficacy correlated with tumor PD-L1 status. Salvage nivolumab/ipilimumab was frequently not feasible and of limited benefit.
PURPOSE: To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage nivolumab/ipilimumab in patients with tumors unresponsive to nivolumab monotherapy. METHODS: Eligible patients with treatment-naive ccRCC received nivolumab until progressive disease (PD), toxicity, or completing 96 treatment weeks (part A). Patients with PD before or stable disease at 48 weeks could receive salvage nivolumab/ipilimumab (part B). The primary end point was improvement in 1-year progression-free survival in patients with tumor PD-L1 expression > 20% versus 0%. RESULTS: One hundred twenty-three patients were enrolled. The objective response rate (ORR) was 34.1% (95% CI, 25.8 to 43.2). ORR by International Metastatic RCC Database Consortium category was favorable-risk 57.1%, intermediate-risk/poor-risk 25.0%, and by sarcomatoid features 36.4%. The ORR was 26.9%, 50.0%, and 75.0% for patients with the tumor PD-L1 expression of 0, 1-20, or > 20%, respectively (trend test P value = .002). The median duration of response was 27.6 (19.3 to not reached) months, with 26 of 42 responders including 17 of 20 with favorable-risk disease remaining progression-free. The 1-year progression-free survival was 34.6% and 75.0% in the PD-L1 = 0% and > 20% categories, respectively (P = .050). Ninety-seven patients with PD or prolonged stable disease were potentially eligible for part B, and 35 were enrolled. The ORR for part B was 11.4%. Grade ≥ 3 treatment-related adverse events occurred in 35% of patients on nivolumab and 43% of those on salvage nivolumab/ipilimumab. CONCLUSION: Nivolumab monotherapy is active in treatment-naive ccRCC. Although efficacy appears to be less than that of nivolumab/ipilimumab in patients with intermediate-risk/poor-risk disease, favorable-risk patients had notable benefit. Efficacy correlated with tumor PD-L1 status. Salvage nivolumab/ipilimumab was frequently not feasible and of limited benefit.
Authors: Toni K Choueiri; Mayer N Fishman; Bernard Escudier; David F McDermott; Charles G Drake; Harriet Kluger; Walter M Stadler; Jose Luis Perez-Gracia; Douglas G McNeel; Brendan Curti; Michael R Harrison; Elizabeth R Plimack; Leonard Appleman; Lawrence Fong; Laurence Albiges; Lewis Cohen; Tina C Young; Scott D Chasalow; Petra Ross-Macdonald; Shivani Srivastava; Maria Jure-Kunkel; John F Kurland; Jason S Simon; Mario Sznol Journal: Clin Cancer Res Date: 2016-05-11 Impact factor: 12.531
Authors: Toni K Choueiri; David J Figueroa; André P Fay; Sabina Signoretti; Yuan Liu; Robert Gagnon; Keith Deen; Christopher Carpenter; Peter Benson; Thai H Ho; Lini Pandite; Paul de Souza; Thomas Powles; Robert J Motzer Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: David F McDermott; Su-Chun Cheng; Sabina Signoretti; Kim A Margolin; Joseph I Clark; Jeffrey A Sosman; Janice P Dutcher; Theodore F Logan; Brendan D Curti; Marc S Ernstoff; Leonard Appleman; Michael K K Wong; Nikhil I Khushalani; Leslie Oleksowicz; Ulka N Vaishampayan; James W Mier; David J Panka; Rupal S Bhatt; Alexandra S Bailey; Bradley C Leibovich; Eugene D Kwon; Fairooz F Kabbinavar; Arie S Belldegrun; Robert A Figlin; Allan J Pantuck; Meredith M Regan; Michael B Atkins Journal: Clin Cancer Res Date: 2014-11-25 Impact factor: 12.531
Authors: Robert J Motzer; Bernard Escudier; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Elizabeth R Plimack; Giuseppe Procopio; David F McDermott; Daniel Castellano; Toni K Choueiri; Frede Donskov; Howard Gurney; Stéphane Oudard; Martin Richardet; Katriina Peltola; Ajjai S Alva; Michael Carducci; John Wagstaff; Christine Chevreau; Satoshi Fukasawa; Yoshihiko Tomita; Thomas C Gauler; Christian K Kollmannsberger; Fabio A Schutz; James Larkin; David Cella; M Brent McHenry; Shruti Shally Saggi; Nizar M Tannir Journal: Cancer Date: 2020-07-16 Impact factor: 6.860
Authors: Nizar M Tannir; Sabina Signoretti; Toni K Choueiri; David F McDermott; Robert J Motzer; Abdallah Flaifel; Jean-Christophe Pignon; Miriam Ficial; Osvaldo Arén Frontera; Saby George; Thomas Powles; Frede Donskov; Michael R Harrison; Philippe Barthélémy; Scott S Tykodi; Judit Kocsis; Alain Ravaud; Jeronimo R Rodriguez-Cid; Sumanta K Pal; Andre M Murad; Yuko Ishii; Shruti Shally Saggi; M Brent McHenry; Brian I Rini Journal: Clin Cancer Res Date: 2020-09-01 Impact factor: 12.531
Authors: Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer Journal: N Engl J Med Date: 2021-03-04 Impact factor: 91.245
Authors: David F McDermott; Jae-Lyun Lee; Georg A Bjarnason; James M G Larkin; Rustem A Gafanov; Mark D Kochenderfer; Niels Viggo Jensen; Frede Donskov; Jahangeer Malik; Alexandr Poprach; Scott S Tykodi; Teresa Alonso-Gordoa; Daniel C Cho; Poul F Geertsen; Miguel Angel Climent Duran; Christopher DiSimone; Rachel Kloss Silverman; Rodolfo F Perini; Charles Schloss; Michael B Atkins Journal: J Clin Oncol Date: 2021-02-02 Impact factor: 44.544
Authors: Miriam Ficial; Opeyemi A Jegede; Miriam Sant'Angelo; Yue Hou; Abdallah Flaifel; Jean-Christophe Pignon; David A Braun; Megan Wind-Rotolo; Maura A Sticco-Ivins; Paul J Catalano; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Catherine J Wu; Michael B Atkins; David F McDermott; Sachet A Shukla; Toni K Choueiri; Sabina Signoretti Journal: Clin Cancer Res Date: 2020-11-20 Impact factor: 12.531
Authors: Robert Motzer; Boris Alekseev; Sun-Young Rha; Camillo Porta; Masatoshi Eto; Thomas Powles; Viktor Grünwald; Thomas E Hutson; Evgeny Kopyltsov; María J Méndez-Vidal; Vadim Kozlov; Anna Alyasova; Sung-Hoo Hong; Anil Kapoor; Teresa Alonso Gordoa; Jaime R Merchan; Eric Winquist; Pablo Maroto; Jeffrey C Goh; Miso Kim; Howard Gurney; Vijay Patel; Avivit Peer; Giuseppe Procopio; Toshio Takagi; Bohuslav Melichar; Frederic Rolland; Ugo De Giorgi; Shirley Wong; Jens Bedke; Manuela Schmidinger; Corina E Dutcus; Alan D Smith; Lea Dutta; Kalgi Mody; Rodolfo F Perini; Dongyuan Xing; Toni K Choueiri Journal: N Engl J Med Date: 2021-02-13 Impact factor: 91.245
Authors: T K Choueiri; R J Motzer; B I Rini; J Haanen; M T Campbell; B Venugopal; C Kollmannsberger; G Gravis-Mescam; M Uemura; J L Lee; M-O Grimm; H Gurney; M Schmidinger; J Larkin; M B Atkins; S K Pal; J Wang; M Mariani; S Krishnaswami; P Cislo; A Chudnovsky; C Fowst; B Huang; A di Pietro; L Albiges Journal: Ann Oncol Date: 2020-04-25 Impact factor: 32.976
Authors: Chung-Han Lee; Martin H Voss; Maria Isabel Carlo; Ying-Bei Chen; Mark Zucker; Andrea Knezevic; Robert A Lefkowitz; Natalie Shapnik; Chloe Dadoun; Ed Reznik; Neil J Shah; Colette Ngozi Owens; Deaglan Joseph McHugh; David Henry Aggen; Andrew Leonard Laccetti; Ritesh Kotecha; Darren R Feldman; Robert J Motzer Journal: J Clin Oncol Date: 2022-03-17 Impact factor: 50.717
Authors: Nizar M Tannir; Daniel C Cho; Adi Diab; Mario Sznol; Mehmet A Bilen; Arjun V Balar; Giovanni Grignani; Erika Puente; Lily Tang; David Chien; Ute Hoch; Arkopal Choudhury; Danni Yu; Sue L Currie; Mary A Tagliaferri; Jonathan Zalevsky; Arlene O Siefker-Radtke; Michael E Hurwitz Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469
Authors: Yuanquan Yang; Sarah P Psutka; Anish B Parikh; Mingjia Li; Katharine Collier; Abdul Miah; Sherry V Mori; Megan Hinkley; Scott S Tykodi; Evan Hall; John A Thompson; Ming Yin Journal: Cancer Med Date: 2022-03-18 Impact factor: 4.711